

# ENDOLOGIX INC /DE/

## **FORM 8-K** (Current report filing)

Filed 06/26/17 for the Period Ending 06/23/17

Address	2 MUSICK IRVINE, CA 92618
Telephone	9495957200
CIK	0001013606
Symbol	ELGX
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Medical Equipment, Supplies & Distribution
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 23, 2017**

**ENDOLOGIX, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**000-28440**

(Commission File Number)

**68-0328265**

(I.R.S. Employer Identification No.)

**2 Musick, Irvine, CA**

(Address of principal executive offices)

**92618**

(Zip Code)

Registrant's telephone number, including area code: **(949) 595-7200**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

As previously reported, on April 3, 2017, Endologix, Inc. (the “Company”) entered into a Credit and Security Agreement (the “Credit Agreement”) with Deerfield ELGX Revolver, LLC, pursuant to which the Company may borrow up to the lesser of \$50 million or its applicable borrowing base from time to time prior to March 31, 2020 (the “Revolver”). On June 23, 2017, the Company drew \$25 million under the Revolver in accordance with the terms and subject to the conditions of the Credit Agreement.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENDOLOGIX, INC.

Date: June 26, 2017

/s/ Vaseem Mahboob

---

Vaseem Mahboob

Chief Financial Officer